Chinese Journal of Dermatology ›› 2026, Vol. 59 ›› Issue (10): 919-934.doi: 10.35541/cjd.20260174
• Guidelines and Consensus • Previous Articles Next Articles
National Center for STD Control, Chinese Center for Disease Control and Prevention; Venereology Group, Chinese Society of Dermatology; Subcommittee on Venereology, China Dermatologist Association
Received:2026-03-31
Revised:2026-09-21
Online:2026-10-15
Published:2026-10-07
Contact:
Wang Qianqiu
E-mail:wangqq@ncstdlc.org
Supported by:National Center for STD Control, Chinese Center for Disease Control and Prevention, Venereology Group, Chinese Society of Dermatology, Subcommittee on Venereology, China Dermatologist Association. Guidelines for diagnosis and treatment of syphilis, gonorrhea, and genital herpes (2026 edition)[J]. Chinese Journal of Dermatology, 2026, 59(10): 919-934.doi:10.35541/cjd.20260174
| [1] | Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations[J]. BMJ, 2004, 328(7454):1490. DOI: 10.1136/bmj.328.7454.1490. |
| [2] | 中国疾病预防控制中心性病控制中心, 中华医学会皮肤性病学分会性病学组, 中国医师协会皮肤科医师分会性病亚专业委员会. 梅毒、淋病、生殖器疱疹、生殖道沙眼衣原体感染诊疗指南(2014)[J]. 中华皮肤科杂志, 2014,47(5):365⁃372. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.05.022. |
| [3] | 中国疾病预防控制中心性病控制中心, 中华医学会皮肤性病学分会性病学组, 中国医师协会皮肤科医师分会性病亚专业委员会. 梅毒、淋病和生殖道沙眼衣原体感染诊疗指南(2020年)[J]. 中华皮肤科杂志, 2020,53(3):168⁃179. DOI: 10.35541/ cjd.20190808. |
| [4] | 中国医师协会皮肤科医师分会临床诊疗指南委员会. 生殖器疱疹临床诊疗指南(2009)[J].中华皮肤科杂志, 2009,42(12):877⁃878. DOI: 10.3760/cma.j.issn.0412⁃4030.2009.12.042. |
| [5] | 中国疾病预防控制中心性病控制中心, 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会. 性传播疾病临床诊疗与防治指南(第二版)[M]. 上海: 上海科学技术出版社, 2020. |
| [6] | 中华人民共和国国家卫生健康委员会. 梅毒诊断:WS 273⁃2018[S]. 北京: 中国标准出版社, 2018. |
| [7] | Zhu L, Gu X, Peng RR, et al. Comparison of the cerebrospinal fluid (CSF) toluidine red unheated serum test and the CSF rapid plasma reagin test with the CSF venereal disease research laboratory test for diagnosis of neurosyphilis among HIV⁃negative syphilis patients in china[J]. J Clin Microbiol, 2014,52(3):736⁃740. DOI: 10.1128/JCM.02522⁃13. |
| [8] | Marra CM, Tantalo LC, Sahi SK, et al. Cxcl13 as a cerebrospinal fluid marker for neurosyphilis in HIV⁃infected patients with syphilis[J]. Sex Transm Dis, 2010,37(5):283⁃287. DOI: 10. 1097/OLQ.0b013e3181d877a1. |
| [9] | 王千秋, 郑晓丽, 杜方智, 等. 遏制梅毒传播:新形势与新策略[J]. 中华皮肤科杂志, 2024,57(3):209⁃212. DOI: 10.35541/cjd.20230729. |
| [10] | National Center for HIV, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of STD Prevention. Sexually transmitted disease surveillance 2020[R/OL]. (2023⁃04⁃10)[2026⁃09⁃19]. https://stacks.cdc.gov/view/cdc/127213. |
| [11] | Riedner G, Rusizoka M, Todd J, et al. Single⁃dose azithromycin versus penicillin G benzathine for the treatment of early syphilis[J]. N Engl J Med, 2005,353(12):1236⁃1244. DOI: 10.1056/NEJMoa044284. |
| [12] | Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. the syphilis and HIV study group[J]. N Engl J Med, 1997,337(5):307⁃314. DOI: 10.1056/NEJM199707313370504. |
| [13] | Dai T, Qu R, Liu J, et al. Efficacy of doxycycline in the treatment of syphilis[J]. Antimicrob Agents Chemother, 2017,61(1):e01092⁃16. DOI: 10.1128/AAC.01092⁃16. |
| [14] | Terris DJ, Moister B, Seybt MW, et al. Outpatient thyroid surgery is safe and desirable[J]. Otolaryngol Head Neck Surg, 2007,136(4):556⁃559. DOI: 10.1016/j.otohns.2006.09.024. |
| [15] | Yim CW, Flynn NM, Fitzgerald FT. Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis[J]. Antimicrob Agents Chemother, 1985,28(2):347⁃348. DOI: 10.1128/AAC.28.2.347. |
| [16] | Kingston M, Apea V, Evans C, et al. BASHH UK guidelines for the management of syphilis 2024[J]. Int J STD AIDS, 2024,35(14):1142⁃1160. DOI: 10.1177/09564624241280406. |
| [17] | Peng RR, Wu J, Zhao W, et al. An observational prospective study based on a large cohort of HIV⁃negative neurosyphilis patients with particular reference to the Jarisch⁃Herxheimer reaction[J]. Eur J Clin Microbiol Infect Dis, 2024,43(6):1073⁃1080. DOI: 10.1007/s10096⁃024⁃04810⁃1. |
| [18] | 中国医师协会皮肤科医师分会性传播疾病专业委员会.梅毒血清固定临床管理专家共识(2023)[J].中华皮肤科杂志,2023,56(5): 383⁃388. DOI: 10.35541/cjd.20220656. |
| [19] | Roberts WC, Bose R, Ko JM, et al. Identifying cardiovascular syphilis at operation[J]. Am J Cardiol, 2009,104(11):1588⁃1594. DOI: 10.1016/j.amjcard.2009.06.071. |
| [20] | Ozturk⁃Engin D, Erdem H, Hasbun R, et al. Predictors of unfavorable outcome in neurosyphilis: multicenter ID⁃IRI study[J]. Eur J Clin Microbiol Infect Dis, 2019,38(1):125⁃134. DOI: 10.1007/s10096⁃018⁃3403⁃7. |
| [21] | Fairley CK, Cornelisse VJ, Hocking JS, et al. Models of gonorrhoea transmission from the mouth and saliva[J]. Lancet Infect Dis, 2019,19(10):e360⁃e366. DOI: 10.1016/S1473⁃3099(19)30304⁃4. |
| [22] | Hui BB, Padeniya TN, Rebuli N, et al. A gonococcal vaccine has the potential to rapidly reduce the incidence of Neisseria gonorrhoeae infection among urban men who have sex with men[J]. J Infect Dis, 2022,225(6):983⁃993. DOI: 10.1093/infdis/jiab581. |
| [23] | Sherrard J, Barlow D. Gonorrhoea in men: clinical and diagnostic aspects[J]. Genitourin Med, 1996,72(6):422⁃426. DOI: 10.1136/sti.72.6.422. |
| [24] | World Health Organization. Guidelines for the management of symptomatic sexually transmitted infections[M/OL]. Geneva: World Health Organization, 2021.(2021⁃07⁃01)[2026⁃08⁃08]. https://iris.who.int/items/fb397c2b⁃02ff⁃4e7e⁃89aa⁃221d411486e7. |
| [25] | Unemo M, Lahra MM, Cole MJ, et al. WHO global gonococcal antimicrobial surveillance programmes, 2019⁃22: a retrospective observational study[J]. Lancet Microbe, 2025,6(10):101181. DOI: 10.1016/j.lanmic.2025.101181. |
| [26] | Centers for Disease Control and Prevention. Recommendations for the laboratory⁃based detection of Chlamydia trachomatis and Neisseria gonorrhoeae⁃⁃2014[J]. MMWR Recomm Rep, 2014,63(RR⁃02):1⁃19. |
| [27] | Fifer H, Doumith M, Rubinstein L, et al. Ceftriaxone⁃resistant Neisseria gonorrhoeae detected in England, 2015⁃24: an observational analysis[J]. J Antimicrob Chemother, 2024,79(12):3332⁃3339. DOI: 10.1093/jac/dkae369. |
| [28] | de Vries H, de Laat M, Jongen VW, et al. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (nabogo): a randomised, non⁃inferiority trial[J]. Lancet Infect Dis, 2022,22(5):706⁃717. DOI: 10.1016/S1473⁃3099(21)00625⁃3. |
| [29] | Ross J, Brittain C, Cole M, et al. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (g⁃tog): a randomised non⁃inferiority trial[J]. Lancet, 2019,393(10190):2511⁃2520. DOI: 10.1016/S0140⁃6736(18)32817⁃4. |
| [30] | Bížová B, Procházka P, Nyčová E, et al. Single⁃dose cefixime 800 mg plus doxycycline 100 mg twice a day for 7 days compared with single⁃dose ceftriaxone 1 g plus single⁃dose azithromycin 2 g for treatment of urogenital, rectal, and pharyngeal gonorrhoea: a randomised clinical trial[J]. Clin Microbiol Infect, 2024,30(2):211⁃215. DOI: 10.1016/j.cmi. 2023.11.006. |
| [31] | Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections[J]. Clin Infect Dis, 1995,20(Suppl 1):47⁃65. DOI: 10.1093/clinids/20.supplement_1.s47. |
| [32] | Chen SC, Yin YP, Dai XQ, et al. First nationwide study regarding ceftriaxone resistance and molecular epidemiology of Neisseria gonorrhoeae in china[J]. J Antimicrob Chemother, 2016,71(1):92⁃99. DOI: 10.1093/jac/dkv321. |
| [33] | Kojima M, Masuda K, Yada Y, et al. Single⁃dose treatment of male patients with gonococcal urethritis using 2g spectinomycin: microbiological and clinical evaluations[J]. Int J Antimicrob Agents, 2008,32(1):50⁃54. DOI: 10.1016/j.ijantimicag.2008. 02.023. |
| [34] | Neubert U, Korting HC, Ruckdeschel G. Susceptibility of Neisseria gonorrhoeae to cefotaxime: in vitro studies and treatment results[J]. Arch Dermatol Res, 1982,274(3⁃4):321⁃326. DOI: 10.1007/BF00403736. |
| [35] | Xiu L, Wang L, Li Y, et al. Molecular screening to track ceftriaxone⁃resistant FC428⁃like Neisseria gonorrhoeae strains' dissemination in four provinces of China, 2019 to 2021[J]. Euro Surveill, 2025,30(6):2400166. DOI: 10.2807/1560⁃7917.ES. 2025.30.6.2400166. |
| [36] | Maatouk I, Vumbugwa P, Cherdtrakulkiat T, et al. Antimicrobial resistance in Neisseria gonorrhoeae in nine sentinel countries within the World Health Organization enhanced gonococcal antimicrobial surveillance programme (EGASP), 2023: a retrospective observational study[J]. Lancet Reg Health West Pac, 2025,61:101663. DOI: 10.1016/j.lanwpc.2025.101663. |
| [37] | Chen SC, Han Y, Yuan LF, et al. Identification of internationally disseminated ceftriaxone⁃resistant Neisseria gonorrhoeae strain FC428, china[J]. Emerg Infect Dis, 2019,25(7):1427⁃1429. DOI: 10.3201/eid2507.190172. |
| [38] | Blouin K, Lefebvre B, Trudelle A, et al. Neisseria gonorrhoeae treatment failure to the recommended antibiotic regimen⁃Québec, Canada, 2015⁃19[J]. J Antimicrob Chemother, 2024,79(11):3029⁃3040. DOI: 10.1093/jac/dkae327. |
| [39] | Eyre DW, Sanderson ND, Lord E, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high⁃level azithromycin resistance, England, February 2018[J]. Euro Surveill, 2018,23(27):1⁃6. DOI: 10. 2807/1560⁃7917.ES.2018.23.27.1800323. |
| [40] | Chen SC, Yuan LF, Zhu XY, et al. Sustained transmission of the ceftriaxone⁃resistant Neisseria gonorrhoeae FC428 clone in China[J]. J Antimicrob Chemother, 2020,75(9):2499⁃2502. DOI: 10.1093/jac/dkaa196. |
| [41] | Yan J, Chen Y, Yang F, et al. High percentage of the ceftriaxone⁃resistant Neisseria gonorrhoeae FC428 clone among isolates from a single hospital in Hangzhou, China[J]. J Antimicrob Chemother, 2021,76(4):936⁃939. DOI: 10.1093/jac/dkaa526. |
| [42] | Unemo M, Golparian D, Oxelbark J, et al. Pharmacodynamic evaluation of ceftriaxone single⁃dose therapy (0.125-1 g) to eradicate ceftriaxone⁃susceptible and ceftriaxone⁃resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea[J]. J Antimicrob Chemother, 2024,79(5):1006⁃1013. DOI: 10.1093/jac/dkae063. |
| [43] | Li X, Le W, Lou X, et al. In vitro activity of ertapenem against Neisseria gonorrhoeae clinical isolates with decreased susceptibility or resistance to extended⁃spectrum cephalosporins in Nanjing, China (2013 to 2019)[J]. Antimicrob Agents Chemother, 2022,66(5):e0010922. DOI: 10.1128/aac.00109⁃22. |
| [44] | Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021[J]. MMWR Recomm Rep, 2021,70(4):1⁃187. DOI: 10.15585/mmwr.rr7004a1. |
| [45] | Rettig PJ, Nelson JD, Kusmiesz H. Spectinomycin therapy for gonorrhea in prepubertal children[J]. Am J Dis Child, 1980,134(4):359⁃363. DOI: 10.1001/archpedi.1980.04490010017006. |
| [46] | Hamasuna R, Yasuda M, Takahashi S, et al. The JAID/JSC guidelines to clinical management of infectious disease 2017 concerning male urethritis and related disorders[J]. J Infect Chemother, 2021,27(4):546⁃554. DOI: 10.1016/j.jiac.2019.12. 001. |
| [47] | Wiesenfeld HC, Meyn LA, Darville T, et al. A randomized controlled trial of ceftriaxone and doxycycline, with or without metronidazole, for the treatment of acute pelvic inflammatory disease[J]. Clin Infect Dis, 2021,72(7):1181⁃1189. DOI: 10. 1093/cid/ciaa101. |
| [48] | Ross J, Guaschino S, Cusini M, et al. 2017 European guideline for the management of pelvic inflammatory disease[J]. Int J STD AIDS, 2018,29(2):108⁃114. DOI: 10.1177/0956462417744099. |
| [49] | Hemsell DL, Little BB, Faro S, et al. Comparison of three regimens recommended by the centers for disease control and prevention for the treatment of women hospitalized with acute pelvic inflammatory disease[J]. Clin Infect Dis, 1994,19(4):720⁃727. DOI: 10.1093/clinids/19.4.720. |
| [50] | Hemsell DL, Martens MG, Faro S, et al. A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women[J]. Clin Infect Dis, 1997,24(Suppl 2):222⁃230. DOI: 10.1093/clinids/24.supplement_2.s222. |
| [51] | Haimovici R, Roussel TJ. Treatment of gonococcal conjunctivitis with single⁃dose intramuscular ceftriaxone[J]. Am J Ophthalmol, 1989,107(5):511⁃514. DOI: 10.1016/0002⁃9394(89)90495⁃9. |
| [52] | Hufstetler K, Llata E, Miele K, et al. Clinical updates in sexually transmitted infections, 2024[J]. J Womens Health (Larchmt), 2024,33(6):827⁃837. DOI: 10.1089/jwh.2024.0367. |
| [53] | Stolz E, Ong L, van Joost T, et al. Treatment of non⁃complicated urogenital, rectal and oropharyngeal gonorrhoea with intramuscular cefotaxime 1.0 g or cefuroxime 1.5 g[J]. J Antimicrob Chemother, 1984,14(Suppl B):295⁃299. DOI: 10. 1093/jac/14.suppl_b.295. |
| [54] | Wongjarit K, Ukritchon S. Disseminated gonococcal infection during two decades in the university hospital, Thailand[J]. Asian Biomed (Res Rev News), 2024,18(3):125⁃132. DOI: 10. 2478/abm⁃2024⁃0018. |
| [55] | Fifer H, Ismail MA, Soni S, et al. British association of sexual health and HIV UK national guideline for the management of infection with Neisseria gonorrhoeae, 2025[J]. Int J STD AIDS, 2025,36(11⁃12):826⁃840. DOI: 10.1177/09564624251345195. |
| [56] | 赵辨. 中国临床皮肤病学[M]. 2版. 南京: 江苏科学技术出版社, 2017. |
| [57] | Wald A, Zeh J, Selke S, et al. Virologic characteristics of subclinical and symptomatic genital herpes infections[J]. N Engl J Med, 1995,333(12):770⁃775. DOI: 10.1056/NEJM1995 09213331203. |
| [58] | Ashley RL, Wald A. Genital herpes: review of the epidemic and potential use of type⁃specific serology[J]. Clin Microbiol Rev, 1999,12(1):1⁃8. DOI: 10.1128/CMR.12.1.1. |
| [59] | 中国中西医结合学会皮肤性病专业委员会性病学组. 生殖器疱疹中西医结合诊疗共识(2020年)[J]. 中华皮肤科杂志, 2020,53(3):180⁃183. DOI: 10.35541/cjd.20190730. |
| [60] | Nilsen A, Aasen T, Halsos A, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes[J]. Lancet, 1982,320(8298):571⁃573. DOI:10.1016/S0140⁃6736(82)92711⁃5. |
| [61] | Spruance SL, Tyring SK, DeGregorio B, et al. A large⁃scale, placebo⁃controlled, dose⁃ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis[J]. Arch Intern Med, 1996,156(15):1729⁃1735. DOI:10.1001/archinte.156.15. 1729. |
| [62] | Sacks SL, Aoki FY, Diaz⁃Mitoma F, et al. Patient⁃initiated, twice⁃daily oral famciclovir for early recurrent genital herpes[J]. JAMA, 1996,276(1):44⁃49. DOI:10.1001/jama.1996.0354001 0046030. |
| [63] | Straus SE, Tariff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes: a placebo⁃controlled double⁃blind trial of oral acyclovir[J]. N Engl J Med, 1984,310(24):1545⁃1550. DOI: 10.1056/NEJM198406143102403. |
| [64] | Engel JP. Long⁃term suppression of genital herpes[J]. JAMA, 1998,280(10):928⁃929. DOI: 10.1001/jama.280.10.928. |
| [65] | Patel R, Moran B, Clarke E, et al. 2024 European guidelines for the management of genital herpes[J]. J Eur Acad Dermatol Venereol, 2025,39(4):742⁃758. DOI: 10.1111/jdv.20450. |
| [1] | Liang Yunsheng. Chronic hand eczema: current status and progress in clinical assessment [J]. Chinese Journal of Dermatology, 2026, 59(9): 850-855. |
| [2] | Tang Zhen¹, Liu Yuhang¹, Yang Ling², Hu Lingxue¹, He Zhijie¹, Cao Kai¹, Ding Shu¹. Value and features of reflectance confocal microscopy in the diagnosis and differential diagnosis of cutaneous lupus erythematosus [J]. Chinese Journal of Dermatology, 2026, 59(9): 873-880. |
| [3] | Li Yanhong, Jiang Kun, Wu Zhuoxuan, Zhang Jianlan, Fang Meizhen, Liu Shuting, Wang Linlin, Hu Lei, Zhou Xiaoyong, Chen Liuqing, Chen Jinbo. Analysis of 18 cases of cutaneous adverse reactions associated with programmed death-1 inhibitors [J]. Chinese Journal of Dermatology, 2026, 59(8): 783-787. |
| [4] | Expert Group on the “Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma ( edition)”. Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma (2026 edition) [J]. Chinese Journal of Dermatology, 2026, 59(8): 728-737. |
| [5] | Chinese Society of Dermatology, China Dermatologist Association. Chinese guideline for the diagnosis and treatment of cutaneous squamous cell carcinoma (2026 edition) [J]. Chinese Journal of Dermatology, 2026, 59(8): 703-716. |
| [6] | Writing Committee Expert Group on “Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement ( edition)”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement (2026 edition) [J]. Chinese Journal of Dermatology, 2026, 59(8): 717-727. |
| [7] | Wei Jin¹, Yan Huiwen¹, Zhang Jianzhong², Lun Wenhui¹. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis complicated by HIV infection: a clinical observation of 10 cases [J]. Chinese Journal of Dermatology, 2026, 59(7): 671-674. |
| [8] | Wang Linlin, Cao Lijuan, Chen Liuqing, Li Dongsheng, Hu Yanyan. Efficacy and safety of hemoporfin-mediated photodynamic therapy for port-wine stains on the extremities: a retrospective analysis [J]. Chinese Journal of Dermatology, 2026, 59(7): 637-644. |
| [9] | Zhang Guolong, Zhao Zijun. Aminolevulinic acid-based photodynamic therapy for cutaneous squamous cell carcinoma: current status, challenges, and perspectives [J]. Chinese Journal of Dermatology, 2026, 59(7): 626-631. |
| [10] | Hu Yu, Lu Yan, Chen Kun, Gu Heng. Standardization, precision, and full-cycle management: interpretation of Specifications for the Management of Vitiligo Patients Undergoing Home Phototherapy [J]. Chinese Journal of Dermatology, 2026, 59(7): 632-636. |
| [11] | Dermatology Professional Committee of Chinese Research Hospital Society, China Dermatologist Association. Guideline for the clinical application of narrowband ultraviolet B phototherapy in dermatology (2026 edition) [J]. Chinese Journal of Dermatology, 2026, 59(7): 595-610. |
| [12] | Photodynamic Therapy Research Cooperative Group, Chinese Society of Dermatology, Chinese Association of Rehabilitation Dermatology & Photodynamic Therapy, Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Guideline for the clinical application of aminolevulinic acid-based photodynamic therapy in the treatment of condyloma acuminatum (2026 edition) [J]. Chinese Journal of Dermatology, 2026, 59(7): 611-618. |
| [13] | He Qing, Zhang Tao, Wang Xiuli, Gao Xinghua, Chen Hongduo, Liu Min, Qi Ruiqun. Biomarkers associated with malignant progression of actinic keratosis [J]. Chinese Journal of Dermatology, 2026, 59(7): 687-690. |
| [14] | Tian Jing, Song Zhiqiang. Application of tape stripping to the detection of biomarkers in atopic dermatitis [J]. Chinese Journal of Dermatology, 2026, 59(6): 578-581. |
| [15] | Pediatric Dermatology Group, Chinese Society of Dermatology, Dermatology Group, Chinese Pediatric Society, Chinese Medical Association, Pediatric Group, Chinese Association of Rehabilitation Dermatology, Atopic Dermatitis Group, Chinese Association of Rehabilitation Dermatology, Pediatric Dermatology Group, China Dermatologist Association, Dermatology Group, the Society of Pediatrics, Chinese Medical Doctor Association. Chinese consensus on the prevention, treatment, and management of atopic dermatitis in children(2026 edition) [J]. Chinese Journal of Dermatology, 2026, 59(6): 487-504. |
|